ANTIDEPRESSANT COMPARATIVE TRIALS SHOULD USE WIDE DOSE RANGE, FDA's LEBER TELLS CONFERENCE; FDA WILL STAY CONSERVATIVE ON COMPARATIVE STUDY REQUIREMENTS
Executive Summary
Antidepressant comparative trials need to compare a wide range of doses, FDA Neuropharmacological Drug Products Division Director Paul Leber, MD, told an FDA conference on "Comparing Treatments: Safety, Effectiveness and Cost-Effectiveness" March 23 in Bethesda, Md.